Filing Flows › Fate Therapeutics (FATE) › Q2 2026 › vs Q2 2025
Fate Therapeutics (FATE) Q2 2026 vs Q2 2025 (year over year)
Fate Therapeutics's revenue rose $175K (+9%) from $1.9M in Q2 2025 to $2.1M in Q2 2026.
Fate Therapeutics, Q2 2026: revenue $2.1M (+9% year over year), net loss $30.2M, operating cash flow −$23.4M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $2.1M | $1.9M | $175K | +9% |
| Other income, net | $975K | $2.9M | −$1.9M | -66% |
| Net loss | $30.2M | $34.1M | −$3.9M | -11% |
| Costs & expenses | $33.2M | $38.9M | −$5.7M | -15% |
| Operating costs | $33.2M | $38.9M | −$5.7M | -15% |
| Research & development | $24.4M | $27.4M | −$3.0M | -11% |
| General & admin | $8.8M | $11.4M | −$2.6M | -23% |
| Operating cash sources | $30.2M | $34.1M | −$3.9M | -11% |
| Depreciation & amortization | $2.8M | $3.3M | −$498K | -15% |
| Share-based compensation | $3.5M | $7.2M | −$3.6M | -51% |
| Working capital & other | $461K | −$949K | $1.4M | — |
| Cash used in operations | $23.4M | $24.6M | −$1.2M | -5% |
| Net loss absorbed | $30.2M | $34.1M | −$3.9M | -11% |
Questions
How much did Fate Therapeutics's revenue grow year over year in Q2 2026?
Fate Therapeutics's revenue rose $175K (+9%) from $1.9M in Q2 2025 to $2.1M in Q2 2026.